Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Genetic Dilated Cardiomyopathy with Dr Nosheen Reza
Author(s): Nosheen Reza Added: 1 month ago
Explore the clinical approach to identifying and managing genetic dilated cardiomyopathy (DCM) with Dr Nosheen RezaThis presentation, part of the comprehensive Cardiomyopathies track, demonstrates how comprehensive family history assessment and systematic genetic evaluation can transform the diagnosis and management of patients presenting with dilated cardiomyopathy, revealing familial patterns… View more

CV Disease in Special Populations

Imaging & Diagnostics
Immune Cell Traits and Heart Failure: A Mendelian Randomisation Study
Author(s): Wei Gao , Hui Wang , Jian-long Wang , et al Added: 2 months ago

Demographic

Heart Failure
Alcohol and Heart Failure
Author(s): Debar Rasoul , Ashwin Ajay , Alend Abdullah , et al Added: 2 years ago

Heart Failure
Dr Phillip Cuculich
Dr Phillip Cuculich graduated from Vanderbilt University School of Medicine, Nashville, USA in 2001 and has since trained at Northwestern University, Chicago and the Barnes-Jewish Hospital, Washington University, St Louis, USA where he is currently an Associate Professor of Medicine in the Cardiovascular Division. His clinical interests include arrhythmias, sudden cardiac death, atrial… View more
Carina Blomström-Lundqvist
Research Area(s) / Expertise: Job title: Professor of Cardiology
Dr Carina Blomström-Lundqvist is Professor of Cardiology at the Department of Cardiology, Institution of Medical Science, Uppsala, SE and Senior Consultant and Professor at the Department of Cardiology and Medical Science, Örebro University Hospital, Örebro, SE. Dr Blomström-Lundqvist graduated in medicine in 1976, she went on to specialise in cardiology and internal medicine, and started… View more
HFSA 25: The ATTRibute-CM Trial
Author(s): Ahmad Masri Added: 3 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in… View more

Heart Failure
Diagnosing Hypertrophic Cardiomyopathy with Dr Sara Saberi
Author(s): Sara Saberi Added: 3 months ago
Master the diagnostic complexities of hypertrophic cardiomyopathy (HCM) with Dr Sara Saberi, a leading expert in inherited cardiovascular diseases.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, provides essential insights into the nuanced approach required for accurate HCM diagnosis and risk stratification.Dr Saberi… View more

Heart Failure
Sanjay Prasad
Job title: Consultant in cardiology and cardiovascular magnetic resonance Professor of cardiomyopathy
Dr. Sanjay Prasad ran the Virgin London Marathon in 2016 to raise money for the Alexander Jansons Foundation, an organisation which was set up to fund research conducted by the Royal Brompton Hospital into causes, prevention and cures for Myocarditis.¹ He is also a musician and used to play in a jazz band. Academic History Dr. Prasad studied for his medical degree at the University of Wales in… View more
Potential Reversibility of ATTR-CM through Anti-ATTR Amyloid Antibodies
Author(s): Marianna Fontana Added: 2 years ago
Prof Marianna Fontana (University College London, UK) joined us to discuss the discovery and impact of antibody-associated reversal of ATTR amyloidosis–related cardiomyopathy in three patients. Prof Fontana and her team, in a correspondence published in The New England Journal of Medicine, revealed the identification of an antibody linked to the spontaneous reversal of cardiac transthyretin… View more

Heart Failure
ESC 23: ATTRibute-CM Trial
Author(s): Julian Gillmore Added: 2 years ago
ESC 2023 — Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study (NCT03860935). ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were… View more

Heart Failure